Table 1.
Patient Demographics, Comorbidities, Laboratory Parameters, and Disease Characteristics
| Characteristic | Overall (N = 356) | MTZ-Based Treatment (n = 255) | Non-MTZ-Based Treatment (n = 101) | P Value |
|---|---|---|---|---|
| Age, y, mean (SD) | 64.3 (17.0) | 65.0 (17.0) | 62.6 (17.1) | .89 |
| Female sex | 209 (58.7) | 147 (57.6) | 62 (61.4) | .52 |
| Race/ethnicity | .57 | |||
| White, non-Hispanic | 222 (62.4) | 162 (63.5) | 60 (59.4) | |
| Black, non-Hispanic | 67 (18.8) | 48 (18.8) | 19 (18.8) | |
| Hispanic | 43 (12.1) | 29 (11.4) | 14 (13.9) | |
| Other/not reported | 24 (6.7) | 16 (6.3) | 8 (7.9) | |
| CCI, median (IQR) | 2 (1–4) | 2 (1–3) | 2 (1–4) | .36 |
| WBC count, cells/μL, mean (SD) | 13 300 (10 500) | 14 100 (11 700) | 11 300 (5800) | .43 |
| Albumin, g/dL, mean (SD) | 3.0 (0.7) | 3.0 (0.7) | 2.9 (0.8) | .16 |
| Severe/fulminant CDIa | 194 (54.5) | 138 (54.1) | 56 (55.4) | .82 |
| ICU admission within 48 h | 54 (15.2) | 38 (14.9) | 16 (15.8) | .82 |
| RT 027 infectionb | 48 (15.2) | 40 (17.5) | 8 (9.1) | .06 |
| HO-CDIa | 158 (44.4) | 104 (40.8) | 54 (53.5) | .02 |
Data are presented as No. (%) unless otherwise indicated. Bolded values indicate those deemed significant with a P value < .05.
Abbreviations: CCI, Charlson Comorbidity Index; CDI, Clostridioides difficile infection; HO-CDI, healthcare facility–onset Clostridioides difficile infection; IQR, interquartile range; MTZ, metronidazole; RT, ribotype; SD, standard deviation; WBC, white blood cell.
aAs defined per Infectious Diseases Society of America 2017 guidelines.
bShown as percentage of 316 isolates with ribotyping completed (228 MTZ-based treatment, 88 non-MTZ-based treatment).